Targeted drugs represented by epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitors (TKIs) have brought revolutionary progress in the treatment of advanced NSCLC (3, 4). This evidence concerns the gene EGFR and non-small cell lung carcinoma.